What the Shingles Vaccine Prevents and Why Every Indian Over 50 Should Ask About It
Shingles is a nerve disease, not a skin disease
Most people who get shingles remember the rash. What they do not forget is the pain that follows it, a condition called post-herpetic neuralgia, where damaged nerve fibres keep firing long after the skin has cleared. This can last months. In some adults over 70, it persists for more than a year. The varicella-zoster virus, the same one that causes chickenpox, never fully leaves the body. It retreats into the dorsal root ganglia, clusters of nerve tissue along the spinal cord, and waits. Decades later, when immunity weakens with age, it reactivates. The rash is just the visible part of a deeper nerve attack.
One in three people will develop shingles in their lifetime, according to the US Centers for Disease Control and Prevention. In India, a 2019 study published in the Indian Journal of Dermatology estimated that the incidence of herpes zoster rises sharply after age 50, with adults over 60 facing the highest burden. The pain can be severe enough to interfere with sleep, appetite, and daily function for months. For older adults managing other conditions, it compounds everything.
What the vaccine actually does
The recombinant zoster vaccine, sold under the brand name Shingrix, is the current standard of care in countries where it is available. A 2019 study in JAMA Internal Medicine, drawing on data from over 14,000 adults, found that Shingrix reduced the risk of shingles by more than 90 percent in adults aged 50 and above. That efficacy held across age groups, including adults over 70, where older live-attenuated vaccines had shown declining effectiveness. The vaccine works by priming the immune system to recognise and suppress the reactivating virus before it can travel down the nerve and cause damage. Two doses are given two to six months apart. Protection does not appear to drop sharply after five years, unlike some other vaccines.
Why Indians over 50 are particularly underprotected
Shingles vaccination is not part of India's Universal Immunisation Programme. It is available in private clinics and select hospitals in cities like Mumbai, Delhi, Bengaluru, and Chennai, but awareness is low and out-of-pocket cost is a barrier. Many adults over 50 in India assume that vaccines are for children, or that shingles is a minor inconvenience rather than a serious nerve condition. The result is that a large portion of the population that had chickenpox as children, which is most adults above 40, carries a dormant virus with no protective immunity boost against reactivation. Comorbidities common in this age group, including diabetes and hypertension, further suppress the immune response and raise shingles risk. Diabetic adults in India are at measurably higher risk of both shingles and its complications, according to data published in the Journal of Diabetes and Its Complications.
Who should ask their doctor about it
The vaccine is recommended for most immunocompetent adults over 50, regardless of whether they remember having chickenpox. Because the virus is so common, most adults in India who grew up before widespread medical record-keeping almost certainly had it. People who are immunocompromised, those on chemotherapy, long-term steroids, or immunosuppressants, need to discuss timing with their doctor, since live-attenuated vaccines carry different considerations. Shingrix is a recombinant vaccine and does not contain live virus, which makes it suitable for a broader range of patients, but the final decision rests on individual clinical history. Side effects are mostly localised: soreness at the injection site, fatigue, and mild fever for a day or two. These are signs of immune activation, not infection.
The question worth asking at your next appointment
Shingles does not always announce itself dramatically. Some adults experience a prodrome of burning or tingling for several days before any rash appears, and in a small percentage of cases, pain occurs without a visible rash at all, a presentation called zoster sine herpete, which is frequently misdiagnosed. By the time the diagnosis is confirmed, the window for antiviral treatment to reduce nerve damage has sometimes passed. Vaccination sidesteps this problem entirely. The conversation to have with a physician is straightforward: given age, immune status, and any underlying conditions, is the shingles vaccine appropriate now?
The answer, for most Indians over 50, is yes. The cost of the vaccine is real. The cost of post-herpetic neuralgia, measured in pain, lost sleep, and compromised function across months, is higher.